NexoBrid® is a topically applied biologic that enzymatically removes burn eschar while preserving healthy tissue—offering a less invasive alternative to surgery. Approved in over 40 countries, including the U.S., EU, and Japan, it transforms burn care by promoting faster healing and reducing complications in both adult and pediatric patients.
NexoBrid development has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA)
